Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MRE (medco research) -- Ignore unavailable to you. Want to Upgrade?

To: Sam who wrote (124)	9/22/1998 12:15:00 PM
From: Harold V	Read Replies (2) \| Respond to of 192

Sam, Congratulations for calling MRE's chart a few days ago. Next time, I'll act on you call!! I haven't seen the articles praising MRE either, and I know nothing of any recent FDA turn down. One of the articles might have been referring to MRE's last two submissions to the FDA, both of which were turned down, both of which were poorly put together, and both of which were non-adenoscine related. After the turn downs, MRE brought on some more savvy scientific advisors, and decided not to push for any non-adenoscine drug approvals. Whether MRE's new drug applications will sail through the FDA approval process is still an open question. From all appearances, the company is sponsoring some very carefully and responsibly designed Phase I, II and III clinical trials. Harold V